



11-04-05

IFW

Attorney Docket No. 9368-5

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Jonathan Smith, et al.

Confirmation No.: 7017

Application No.: 10/804,331

Group Art Unit: 1648

Filed: March 19, 2004

For: *Alphavirus Replicons And Helper Constructs*

Date: November 3, 2005

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

PURSUANT TO 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

Respectfully submitted,

Mary L. Miller
Registration No. 39,303

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF MAILING UNDER 37 CFR § 1.10

Express Mail Label No.: EV 675795819 US

Date of Deposit: November 3, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	9368-5
-------	---	----	---	------------------------	--------

Complete if Known

Application Number	10/804,331
Filing Date	March 19, 2004
First Named Inventor	Jonathan Smith
Group Art Unit	1648
Examiner Name	TBA

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1.	US-5,827,658		Liang et al.	10/27/1998
	2.	US-2004/0029279		Kovacs et al.	02/12/2004
	3.	US-2005/0118251		Nagata et al.	06/02/2005
	4.	US-2003/0148262		Polo et al.	08/07/2003
	5.	US-2003/0232324		Polo et al.	12/18/2003

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			
	6.	WO	99/51263		MacDonald et al.	10/14/1999	

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	7.	Davis et al. "Alphavirus Replicon Particles as Candidate HIV Vaccines" <i>IUBMB Life</i> 53: 209-211 (2002)	
	8.	Baric et al. "Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons" <i>Journal of Virology</i> 76(6): 3023-3030 (2002)	
	9.	Eiben et al. "Establishment of an HLA-A*0201 Human Papillomavirus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A*0201 Transgenic Mice" <i>Cancer Research</i> 62: 5792-5799 (2002)	
	10.	Eralp et al. "Doxorubicin and Paclitaxel Enhance the Antitumor Efficacy of Vaccines Directed Against HER 2/neu in a Murine Mammary Carcinoma Model" <i>Breast Cancer Research</i> 6:R275-R283 (2004)	
	11.	Lee et al. "Candidate Vaccine Against Botulinum Neurotoxin Serotype A Derived from a Venezuelan Equine Encephalitis Virus Vector System" <i>Infection and Immunity</i> 69(9): 5709-5715 (2001)	
	12.	Lee et al. "Immune Protection Against Staphylococcal Enterotoxin-Induced Toxic Shock by Vaccination with a Venezuelan Equine Encephalitis Virus Replicon" <i>Journal of Infectious Diseases</i> 185: 1192-1196 (2002)	
	13.	MacDonald et al. "Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis" <i>Journal of Virology</i> 74(2): 914-922 (2000)	
	14.	Nelson et al. "Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-Tumor Immunity to the "self" Tumor-Associated Antigen, <i>neu</i> in a Rat Mammary Tumor Model" <i>Breast Cancer Research and Treatment</i> 63R: 1-15 (2003)	
	15.	Pushko et al. "Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs Against Infection with Lassa and Ebola Viruses" <i>Journal of Virology</i> 75(23): 11677-11685 (2001)	
	16.	Schultz-Cherry et al. "Influenza Virus (A/HK/156/97) Hemagglutinin Expressed by an Alphavirus Replicon System Protects Chickens Against Lethal Infection with Hong Kong-Origin H5N1 Viruses" <i>Virology</i> 278: 55-59 (2000)	
	17.	Wang et al. "Alphavirus Replicon Particles Containing the Gene for HER2/neu Inhibit Breast Cancer Growth and Tumorigenesis" <i>Breast Cancer Research</i> 7: R145-R155 (2005)	
	18.	Velders et al. "Eradication of Established Tumors by Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering Human Papillomavirus 16 E7 RNA" <i>Cancer Research</i> 61: 7861-7867 (2001)	
	19.	Wilson et al. "Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein" <i>Journal of Virology</i> 75(6): 2660-2664 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.